AUTHOR=Al Hashmi Khamis , Giglio Rosaria Vincenza , Pantea Stoian Anca , Patti Angelo Maria , Al Waili Khalid , Al Rasadi Khalid , Ciaccio Marcello , Rizzo Manfredi TITLE=Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies JOURNAL=Frontiers in Nutrition VOLUME=11 YEAR=2024 URL=https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2024.1355732 DOI=10.3389/fnut.2024.1355732 ISSN=2296-861X ABSTRACT=
The definition of “Metabolic Associated Fatty Liver Disease – MAFLD” has replaced the previous definition of Nonalcoholic Fatty Liver Disease (NAFLD), because cardiometabolic criteria have been added for the prevention of cardiological risk in these patients. This definition leads to an in-depth study of the bidirectional relationships between hepatic steatosis, Type 2 Diabetes Mellitus (T2DM), Cardiovascular Disease (CVD) and/or their complications. Lifestyle modification, which includes correct nutrition combined with regular physical activity, represents the therapeutic cornerstone of MAFLD. When therapy is required, there is not clear accord on how to proceed in an optimal way with nutraceutical or pharmacological therapy. Numerous studies have attempted to identify nutraceuticals with a significant benefit on metabolic alterations and which contribute to the improvement of hepatic steatosis. Several evidences are supporting the use of silymarin, berberine, curcumin,